Response to Kourtis et al. 'Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis' [2]

AIDS

Volumn 21, Issue 12, 2007, Pages 1656-1657

  Patel, Deven ^a   Thorne, Claire ^a   Newell, Marie Louise ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; PROTEINASE INHIBITOR;

CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG USE; FIRST TRIMESTER PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MONOTHERAPY; PREMATURE LABOR; PRIORITY JOURNAL; RISK FACTOR; SECOND TRIMESTER PREGNANCY; TREATMENT DURATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MATERNAL-FETAL EXCHANGE; META-ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH;

EID: 34447548841     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32826fb753     Document Type: Letter

References (12)

1. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-615.
2. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315:1533-1537.
3. Thorne C, Rudin C, Newell ML, Kind C, Hug I, Gray L, Peckham CS, European Collaborative Study and the Swiss Mother+Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-2920.
4. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al. Lamivudine-zidovudine combination for the prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-2093.
5. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870.
6. Thorne C, Patel D, Newell ML, European Collaborative Study. Increased risk of adverse pregnancy outcomes in HAART-treated HIV-infected women in Europe. AIDS 2004; 18:2337-2339.
7. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38:449-473.
8. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or still-birth? J Infect Dis 2006; 193:1195-1201.
9. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 2007; 119:e900-e906.
10. Ravizza M, Martinelli P, Bucceri A, Fiore S, Alberico S, Tamburrini E, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195:913-914.
11. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026.
12. Fiore S, Newell ML, Trabattoni D, Thorne C, Gray L, Savasi V, et al. Antiretroviral therapy-associated modulation of Th-1 and Th-2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70:143-150.